# A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct03952143` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03952143](<https://clinicaltrials.gov/study/NCT03952143>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03952143

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 628 participants.

## Technical summary

Registry record NCT03952143. Randomized; double masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2021-01-20 (actual). Results posted on 2022-02-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 628 participants (enrolled count; ClinicalTrials.gov record NCT03952143, source copy `cardio:ctgov-nct03952143-2022-02-08`, retrieved 2026-10-26)
- Started: 2019-05-27 (actual) (ClinicalTrials.gov record NCT03952143, source copy `cardio:ctgov-nct03952143-2022-02-08`, retrieved 2026-10-26)
- Primary completion: 2021-01-20 (actual) (ClinicalTrials.gov record NCT03952143, source copy `cardio:ctgov-nct03952143-2022-02-08`, retrieved 2026-10-26)
- Completion: 2021-01-20 (actual) (ClinicalTrials.gov record NCT03952143, source copy `cardio:ctgov-nct03952143-2022-02-08`, retrieved 2026-10-26)
- Results first posted: 2022-02-08 (ClinicalTrials.gov record NCT03952143, source copy `cardio:ctgov-nct03952143-2022-02-08`, retrieved 2026-10-26)
- Countries: Argentina; China; Mexico (ClinicalTrials.gov record NCT03952143, source copy `cardio:ctgov-nct03952143-2022-02-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03952143-2022-02-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): LY900014
- Intervention (Drug): Insulin Lispro
- Intervention (Drug): Insulin Glargine
- Intervention (Drug): Insulin Degludec
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 227913a7d9b9dcf21ae7377f5d404f236b7dd5355b86d05e1c422852163a420d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
